Comments

However, I’d like to point out one error and make one other suggestion:

1. The terminology in the I/O question is incorrect, in terms of the therapeutic modality of “checkpoint inhibitors” (e.g. Ipilimumab) vs. their targets, “T-cell inhibitory checkpoints” (e.g. CTLA-4). CTLA-4 and PD-1 are NOT “checkpoint inhibitors”; they are the targets of those inhibitors, most of which are monoclonal antibodies (mAbs). Some people use slang for this new class of drugs, like saying “Roche’s PD-1”, which is supposed to be a shorter way of saying “Roche’s anti-PD-1 drug”, but I find this to be unecessary and the grounds for a lot of confusion.

2. In English, it sounds odd to say “between 2018 and 2015”, as you’re going backwards in time. Consider expressing the range as “from 2015 to 2018”.

Thanks for pointing out the error of our ways. We’ll correct the reference to checkpoint inhibitor– and the reference to the Nature Reviews article actually should have said 2010-2015–so we’ll need to fix that as well. I do hope you continue enjoying our quizzes. Have a great new year!

July 1, 2019What’s the Buzz? Test Your Knowledge of HoneybeesBees and other pollinators are crucial for our food supply. In recent years, researchers have found worrying evidence that pollinators are adversely affected by climate change, which in […]